ASTELLAS PHARMA A/S: Financial statements 2015
CVR: 10888638
Source: annual report 2015, Danish Business Authority
01/04/2014 – 31/03/2015
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2015. In 2015, the company reported revenue of EUR 121,936,000 and a net result of EUR 5,258,000 compared with EUR 6,989,000 the year before. That is an increase of 25.7% compared with the year before. The profit margin was 4.3%. Equity in the 2015 report amounted to EUR 38,694,000. The solvency ratio was 48.6%. The company had 116 employees in the financial year.
- Revenue
- EUR 121,936,000
- Gross Profit
- EUR 25,848,000
- Profit/Loss
- EUR 5,258,000
- Equity
- EUR 38,694,000
- Total Assets
- EUR 79,572,000
- Employees
- 116
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | 121.9 mio. EUR | 25.8 mio. EUR | 5.3 mio. EUR | 38.7 mio. EUR | 116 |
| 2014 | 97 mio. EUR | 26.5 mio. EUR | 7 mio. EUR | 38.4 mio. EUR | 112 |
| 2013 | 93 mio. EUR | 23.6 mio. EUR | 5.7 mio. EUR | 34.4 mio. EUR | 90 |
Official annual report
How creditworthy is ASTELLAS PHARMA A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of February 10, 2015, is registered as an owner of ASTELLAS PHARMA A/S with an ownership share of 100%.
About ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.